← All trials
NCT06429384
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2023
- Primary completion
- Nov 18, 2023
- Completion date
- Dec 24, 2023
- First posted
- May 28, 2024
- Last posted
- Jun 4, 2024
- Enrollment
- 240
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversitySponsor investigator
- Capital Medical UniversityOfficial
- NeuroDawn Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.